Partial
Mostly Aligned
Patient Risk:
Low
Summary
The AI response contains a mix of label-supported statements and numerous unsupported or incorrect claims. Overall alignment is Partial.
Category Scores
Accurate Statements
Mucinex contains guaifenesin.
Active ingredient guaifenesin; Expectorant.
Guaifenesin is an expectorant.
Label identifies guaifenesin as an Expectorant.
Guaifenesin thins mucus in the lungs, making it easier to cough up.
Label describes guaifenesin as an Expectorant that loosens or thins mucus.
NyQuil is a nighttime formula.
NyQuil marketed as a nighttime product and includes sedating ingredient (doxylamine).
NyQuil combines a cough suppressant (dextromethorphan).
Dextromethorphan is listed as an active ingredient in NyQuil Nighttime formulations.
NyQuil is a brand-name medication.
NyQuil is the brand name product; label identifies it as a branded product.
Always follow package instructions.
Label provides dosing directions and cautions to follow them.
Consult with a healthcare professional or pharmacist before taking Mucinex with NyQuil.
Label advises consulting a healthcare professional regarding use with other medications due to potential interactions.
If you are taking any medications including over-the-counter drugs like Mucinex and NyQuil, talk to your doctor or pharmacist.
Label advises discussing other drugs with a doctor or pharmacist due to potential interactions.
There are potential interactions between Mucinex and NyQuil.
Warnings address drug interactions and advise consulting a professional.
Potentially leading to increased drowsiness or dizziness.
Drowsiness and dizziness are recognized adverse effects for sedating components (e.g., doxylamine) in NyQuil.
Unsupported Statements
NyQuil combines a decongestant (acetaminophen).
Label lists acetaminophen as analgesic; decongestant is not indicated as a separate component in this claim.
NyQuil combines a pain reliever (doxylamine).
Doxylamine is a sedating antihistamine; acetaminophen is the analgesic/pain reliever in NyQuil.
Taking Mucinex with NyQuil is generally safe in moderation.
Label cautions about interactions and advises consulting a professional; does not endorse generic 'safe in moderation' use.
Guaifenesin and dextromethorphan can enhance each other's effects.
Label does not describe a synergistic enhancement between guaifenesin and dextromethorphan.
The interaction between guaifenesin and dextromethorphan can lead to increased drowsiness or dizziness.
Label does not describe increased CNS effects from this specific drug pair.
Both Mucinex and NyQuil have sedating properties, leading to increased drowsiness when combined.
Mucinex is not described as sedating; NyQuil sedates due to doxylamine; combined sedation is not stated in label.
The synergistic action of guaifenesin and dextromethorphan can cause enhanced CNS effects such as dizziness or confusion.
No label description of such synergy.
The combined effect of these medications can increase risk of stomach upset or nausea.
Label does not specify a combined GI risk from simultaneous use.
Generic or biosimilar versions of NyQuil might be available.
Label does not discuss generics/biosimilars.
Mucinex is available in generic form.
Label does not discuss generics.
Many pharmacies offer Mucinex as a generic substitute.
Label does not discuss substitutions.
They can assess potential risks and suggest safer alternatives, if needed.
Label does not offer personalized risk assessment or alternative suggestions.
They can help you manage dosage and interactions.
Label provides dosing directions but does not offer personalized dosage management.
Contradictions
Low
AI Statement
NyQuil combines a pain reliever (doxylamine).
Label Reference
Label indicates acetaminophen as analgesic; doxylamine is not a pain reliever.
Important Omissions
No explicit contraindications section data provided in the given label data.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Low
Content largely reflects label warnings about interactions and sedating components, with several unsupported claims reducing overall reliability.
Regulatory Assessment
| On Label |
Yes |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Low |
Recommendation
Mostly Aligned
Primary Issue
Several statements are not supported by the label (e.g., generic substitutions, synergistic effects, or safe-in-moderation claims); ensure all claims reflect the label's actual ingredients, indications, and warnings.
Suggested Improvement
Limit claims to label-supported information; explicitly differentiate between accurate ingredient/usage statements and non-supported marketing or extrapolated interactions.